Erectile dysfunction: a randomised controlled trial of lipid lowering with simvastatin (EDS trial)

niversity of Hertfordshire (UK)0 个研究点目标入组 170 人开始时间: 2008年9月26日最近更新: 2016年10月17日

试验速览

暂无简介。

•1. Men aged 40 years and over
•2. In a stable heterosexual relationship for at least 6 months
•3. No clinically overt cardiovascular risk factors other than raised cholesterol
•4. Not currently on lipid or erectile dysfunction therapy
•5. Untreated erectile dysfunction defined as score <22 on the International Index of Erectile Function 5 item questionnaire

•1. Diabetes, past history of myocardial infarction, hospitalised angina or stroke
•2. Hypertension - systolic blood pressure >=170 mmHg, diastolic >=100 mmHg
•3. Ratio total:high-density lipoproteins (HDL) cholesterol >=6
•4. Total cardiovascular risk >= 20% over next 10 years
•5. Current lipid lowering therapy
•6. Erectile dysfunction therapy in the last 3 months
•7. Hypogonadism
•8. Chronic liver disease or abnormal liver function
•9. Severe renal disease or evidence of impaired renal function
•10. Inflammatory muscle disease or evidence of muscle problems
•11. Concomitant administration of contra-indicated drugs: itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, telithromycin and nefazodone
•12. Concomitant administration of other drugs associated with increased risk of myopathy/rhabdomyolysis: ciclosporin, danazol and fusidic acid
•13. Galactose intolerance, Lapp lactase deficiency or glocose-galactose malabsorption

发起方

niversity of Hertfordshire (UK)